PREdiction of Chronic LUng Allograft Dysfunction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

240 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-10

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic lung allograft dysfunction (CLAD) is the leading cause of long-term mortality after lung transplantation. Several risk factors for CLAD have been identified, but the exact pathophysiology and triggering molecular factors remain largely unknown. Moreover, in clinical practice, no integration of the different risk factors is achieved. CLAD is therefore diagnosed most often late with the persistent decline in respiratory function, revealing a profound and irreversible alteration of the pulmonary graft. Several blood biomarkers that can predict the occurrence of CLAD more than 6 months before clinical diagnosis have been identified and validated. From these preliminary results, a composite score is being developed from independent samples from the COLT (COhort in Lung Transplantation) cohort. The main objective of this project is to validate this robust and predictive composite score (biological and clinical) of CLAD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CLAD: Finding Biomarkers to Predict Rejection and/ or Outcome After Lung Transplantation

NCT04558333

Lung Transplant Failure and Rejection Primary Graft Dysfunction

TERMINATED

CLAD Phenotype Specific Risk Factors and Mechanisms

NCT02631720

Lung Transplant Post Lung Transplantation

COMPLETED

Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation

NCT04837339

Lung Transplant Rejection Lung Transplant Failure Lung Transplant; Complications +1 more

RECRUITING NA

Lung Clearance Index and Lung Allograft Dysfunction

NCT03850002

Lung Transplantation Chronic Lung Allograft Dysfunction Rejection Lung Transplant

WITHDRAWN

Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant

NCT03697395

Chronic Rejection of Lung Transplant

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Transplant Rejection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lung transplant

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients to receive lung transplants awaiting registration on the transplant waiting list
* Patients affiliated to a social security system
* Patients who have given their informed consent
* Patients weighing more than 26 kg
* Patients over 16 years of age

Exclusion Criteria

* Pregnant or breastfeeding women
* Patients unable to follow the protocol
* Patients with concomitant inflammatory diseases, regardless of acute, chronic or infectious rejection.
* Patients with a history of cancer in remission for less than 5 years, with the exception of localized skin cancers, excluding melanoma.

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No